4/3
07:26 am
pcvx
Vaxcyte, Inc. (NASDAQ: PCVX) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Medium
Report
Vaxcyte, Inc. (NASDAQ: PCVX) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
3/31
07:11 am
pcvx
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study [Yahoo! Finance]
Low
Report
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study [Yahoo! Finance]
3/31
07:00 am
pcvx
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
High
Report
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
3/30
05:00 pm
pcvx
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
High
Report
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
3/25
08:27 am
pcvx
Vaxcyte (PCVX) Struggled Amid Political Uncertainty [Yahoo! Finance]
Low
Report
Vaxcyte (PCVX) Struggled Amid Political Uncertainty [Yahoo! Finance]
3/14
08:16 pm
pcvx
Market Correction: This Dirt Cheap ETF Is Down by Almost 20% [Yahoo! Finance]
Low
Report
Market Correction: This Dirt Cheap ETF Is Down by Almost 20% [Yahoo! Finance]
3/12
10:12 am
pcvx
Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $160.00 price target on the stock.
Low
Report
Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $160.00 price target on the stock.
2/26
11:36 am
pcvx
Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $160.00 price target on the stock.
Medium
Report
Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $160.00 price target on the stock.
2/26
08:00 am
pcvx
Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $140.00 price target on the stock.
Low
Report
Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $140.00 price target on the stock.
2/26
02:28 am
pcvx
Vaxcyte, Inc. 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
Low
Report
Vaxcyte, Inc. 2024 Q4 - Results - Earnings Call Presentation [Seeking Alpha]
2/25
07:07 pm
pcvx
Vaxcyte, Inc. (PCVX): Among the Stocks That Will Go to The Moon According to Analysts [Yahoo! Finance]
Low
Report
Vaxcyte, Inc. (PCVX): Among the Stocks That Will Go to The Moon According to Analysts [Yahoo! Finance]
2/25
04:01 pm
pcvx
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Low
Report
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2/12
04:28 pm
pcvx
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 [Yahoo! Finance]
Low
Report
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 [Yahoo! Finance]
2/12
04:05 pm
pcvx
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
Low
Report
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
2/11
08:09 am
pcvx
Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.
Low
Report
Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $14.00 price target on the stock.
2/5
08:00 am
pcvx
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
Low
Report
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
1/30
04:05 pm
pcvx
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
Medium
Report
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
1/30
11:51 am
pcvx
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
Low
Report
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
1/15
07:16 am
pcvx
https://seekingalpha.com/article/4749593-vaxcyte-aims-to-outshine-pfizer-with-bold-vax-31-strategy [Seeking Alpha]
Medium
Report
https://seekingalpha.com/article/4749593-vaxcyte-aims-to-outshine-pfizer-with-bold-vax-31-strategy [Seeking Alpha]
1/7
07:25 am
pcvx
Sling Therapeutics Appoints Andrew Guggenhime to its Board of Directors [Yahoo! Finance]
Low
Report
Sling Therapeutics Appoints Andrew Guggenhime to its Board of Directors [Yahoo! Finance]
1/7
01:13 am
pcvx
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
Low
Report
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm